Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > AACR - late breaking absracts text posted by noon today

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Apr 14, 2023 2:15pm

92 Views

Post# 35395689

RE:RE:RE:RE:RE:RE:AACR - late breaking absracts text posted by noon today

I understood that incorrectly.

"Increased inhibition of tumor growth" means that the treatment being tested was able to slow down or stop the growth of cancerous tumors more effectively than other treatments or when the same treatments were used alone. Essentially, it means that the combination of TH1902 and anti-PD-L1 agents showed promise in potentially being a more effective treatment for cancer.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1